

sildenafil for PAH

sildenafil (REVATIO)

sildenafil suspension (LIQREV)

Diagnosis Considered for Coverage:

- Pulmonary Arterial Hypertension (WHO Group I Pulmonary Hypertension)
- Raynaud's phenomenon

Coverage Criteria:

For Pulmonary Arterial Hypertension (WHO Group I Pulmonary Hypertension):

- WHO group 1 classification, **and**
- Dose does not exceed 60 mg per day, **and**
- **For Liqrev request**: Intolerance or contraindication with sildenafil tablet and oral suspension formulations (Revatio) not expected with Liqrev.

For Raynaud's phenomenon:

- Inadequate response, intolerable side effect, or contraindication with a calcium channel blocker (e.g., nifedipine, felodipine, amlodipine), **and**
- Dose does not exceed 200 mg per day.

Coverage Duration: one year

Effective: 01/31/2024